IPO league tables: Relypsa and Insys snag biotech boom top spots
This article was originally published in Scrip
Executive Summary
Relypsa has snagged the top spot as the 2013 biopharma IPO debutant with the highest daily share price growth rate. It pipped to the post Insys Therapeutics, which showed the highest absolute growth since its IPO, but which had over six months more to reap the benefits of the biotech boom on the US public markets.